Subtle, cumulative, slow-onset. Like astaxanthin, this is a "rust-proofing" supplement, not a felt nootropic.

• Onset: No acute felt effect. Plasma peaks at 1-2 hr (Meriva, Theracurmin) or 4-6 hr (unformulated, with piperine). Tissue accumulation requires 1-4 weeks; clinical endpoints typically need 6-12 weeks.
• Peak/plateau: After 4-8 weeks of consistent dosing, observable effects are: reduced morning joint stiffness, faster bounce-back from hard training (CK / DOMS effect), incrementally cleaner skin, possibly subtle mood lift if baseline inflammation was high. Cognitive effects (working memory, attention) are typically only noticed after 8-12 weeks at adequate dose.
• Taper: Effects fade gradually over 2-4 weeks after stopping. No withdrawal.
• What it does NOT feel like: Not a stimulant, not an acute mood lifter, not an analgesic in the felt sense (it doesn't reduce acute pain — it reduces chronic low-grade inflammation underlying pain). Don't expect Tuesday-afternoon-different.

For Dylan specifically: the felt benefits will most likely cluster around (1) faster recovery between hard sessions (less DOMS, less stiffness), (2) less joint creak from sparring volume, and (3) over months, a baseline reduction in the "low background inflammation" that comes with high-volume training + computer work. Mood and cognitive benefits if present are slow and indirect.

• Tolerance buildup: None. Mechanism is enzymatic / transcriptional, not receptor-mediated. No tolerance reported across multi-year use studies.
• Recommended cycle: None. Daily continuous use is the standard protocol in all clinical trials (4 weeks to 18 months).
• Reset protocol: Not applicable.
• Long-term safety: Multi-year use up to 18 months in Small 2018 was clean. Multi-decade dietary use in South Asia at curry-level intake (~100-200 mg curcuminoids/day) shows no population-level safety signal. The DILI signal is in the supplement-form, not the dietary-form.

Synergistic with

• omega-3 / DHA (Dylan's V4 Carlson DHA Gems): Strongly synergistic. Both anti-inflammatory at the lipid mediator level (DHA → resolvins/protectins; curcumin → NF-κB / COX-2 / lipoxygenase). Both anti-amyloid. Animal AD models consistently show curcumin + DHA > either alone. The fat from fish oil softgels also marginally enhances Meriva absorption. Same breakfast dose — already correct in V4.
• astaxanthin (Dylan's V5 add): Different mechanisms, layered protection. Astaxanthin = membrane-spanning lipid antioxidant (carotenoid); curcumin = NF-κB / Nrf2 polyphenol. Both fat-soluble, both BBB-crossing, both anti-inflammatory via different routes. Take together at breakfast. The V4 + V5 stack of curcumin + DHA + astaxanthin + NAC is the canonical "brain protection" quadruple.
• n-acetyl-cysteine (NAC) (Dylan's V4 Swanson NAC): NAC is the glutathione precursor; curcumin is the Nrf2 activator that upregulates the enzymes glutathione synthesis depends on. Together they raise both substrate (NAC → cysteine → GSH) and enzyme capacity (curcumin → γ-GCS, GSH reductase). Layered antioxidant defense. No interaction concern. Both already in V4.
• piperine (BioPerine): Inhibits intestinal glucuronidation of curcumin → ~20× AUC. Useful at low doses (5-10 mg piperine per 500 mg unformulated curcumin). Less needed when using Meriva or Theracurmin — those formulations already solve bioavailability. Adding piperine to Meriva is not contraindicated but redundant. Piperine has its own broad CYP inhibition (CYP3A4, CYP2C8, CYP2D6) — see Drug Interactions.
• boswellia (Boswellia serrata; AKBA): Different anti-inflammatory pathway (5-LOX inhibition); commonly stacked for OA and inflammatory conditions. CuraMed / CurcuMin Plus brands often combine. Synergistic in OA trials (Curcuma + Boswellia > either alone in Antony 2011, Kizhakkedath 2013).
• resveratrol / pterostilbene: Both polyphenols; different targets (SIRT1 for resveratrol). Stacking is reasonable; no interaction concern.
• vitamin D3 (Dylan's V4 CGN D3 + K2): Vitamin D and curcumin both modulate immune/inflammatory signaling. Some preclinical synergy in colon health and bone. No interaction concern. Both at breakfast.
• vitamin C (Dylan's V4 CGN Vitamin C): Aqueous-phase antioxidant complementing curcumin's lipid-phase / pleiotropic action. No interaction.
• green tea / EGCG: Both polyphenols, both anti-inflammatory, layered. Mild additive CYP inhibition — flag for high-dose users on narrow-therapeutic drugs.
• apigenin (Dylan's V5 add): Both flavonoid-ish polyphenols, both anti-inflammatory + senomorphic-adjacent. No interaction. Layered "longevity-tier" stack. Both at breakfast or per Dylan's apigenin dose timing.
• ALCAR + alpha-lipoic acid: Mitochondrial stack adjacent to curcumin; layered cellular energy + anti-inflammatory protection.
• quercetin: Both polyphenols; both NF-κB inhibitors; quercetin is also senolytic. Reasonable stack; mild additive CYP3A4 / CYP2C9 inhibition.

Avoid stacking with

• High-dose anticoagulants (warfarin, DOACs) + high-dose curcumin (>1500 mg/day Meriva): Additive bleeding risk. Not relevant to Dylan.
• Strong aromatic CYP3A4 substrates with narrow therapeutic index (cyclosporine, tacrolimus, certain chemotherapeutics like docetaxel/imatinib): theoretical interaction via curcumin's modest CYP3A4 inhibition. Worth flagging only at high doses.
• Iron supplements: if iron-deficiency-anemic and supplementing iron, take iron 4 hr separated from curcumin to avoid chelation reducing iron absorption. Not relevant unless ferritin comes back low on June panel.
• Active gallstones / biliary disease: contraindicated regardless of stack.

Neutral / safe co-administration

• All V4 stack items: NAC (synergistic), citicoline, magnesium glycinate + threonate, fish oil (synergistic), phosphatidylserine, rhodiola, theanine, glycine/tryptophan, D3 + K2, beta-alanine, vitamin C (mild synergy), creatine.
• All V5 planned items: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, taurine, astaxanthin (synergistic), L-tryptophan.
• Caffeine — no interaction, safe.
• Standard NSAIDs, acetaminophen — safe at sensible doses; curcumin's mild GI effects don't compound NSAID gastropathy.

Curcumin is a mild-to-moderate inhibitor of multiple CYP enzymes and transporters; clinical relevance at supplemental doses is generally modest because of the bioavailability ceiling, but matters for narrow-therapeutic-index drugs and at high formulated doses:

• CYP3A4: Modest reversible inhibition. Drugs to watch: many statins (simvastatin, atorvastatin), midazolam, alfentanil, tacrolimus / cyclosporine (transplant — flagged), some calcium channel blockers, norethindrone-containing contraceptives (very rare contraceptive failure case reports at high curcumin doses; magnitude probably small but not zero).
• CYP2C9: Inhibition reported in vitro and in some PK studies. Drugs to watch: warfarin (bleeding risk — case reports), NSAIDs, some sulfonylureas, fluvastatin, irbesartan, losartan.
• CYP1A2: Mild inhibition. Drugs to watch: caffeine (curcumin's CYP1A2 inhibition could mildly extend caffeine half-life — at Dylan's caffeine doses this is negligible), theophylline, clozapine.
• CYP2D6: Modest inhibition. Drugs to watch: many antidepressants (fluoxetine, paroxetine, venlafaxine), some opioids (tramadol — codeine activation reduced), tamoxifen.
• P-glycoprotein: Curcumin inhibits P-gp at high concentrations. Drugs to watch: digoxin, some chemotherapeutics, fexofenadine.
• Sulfotransferases / UGT: Curcumin inhibits SULT1A1 and UGT1A — relevant for sulfated/glucuronidated drugs (acetaminophen at toxic doses, some thyroid hormone metabolism).
• Anticoagulants / antiplatelets (warfarin, DOACs, aspirin, clopidogrel): Mild antiplatelet activity at high doses + CYP2C9 inhibition for warfarin → theoretical and case-reported bleeding amplification. Watch INR if on warfarin.
• Hormonal / contraceptive: Very rare case reports of contraceptive failure with high-dose curcumin (>1500 mg/day) co-administered with combined oral contraceptives — likely via CYP3A4 induction in some users (curcumin can be a weak inducer in chronic exposure, opposite direction from acute inhibition). Magnitude debated; for users on hormonal contraception relying on CYP3A4 metabolism, flag the risk and recommend backup method during the first 2-4 weeks of high-dose curcumin or formulation change. Not applicable to Dylan; relevant if a partner is on OCP.
• Iron supplementation: Chelation reduces iron absorption when co-administered. Separate by 4+ hr if both needed.

For Dylan: not on any of the watch-list drugs. The caffeine + curcumin combination is mild and irrelevant at his dose. No drug interactions of concern in V4/V5 stack.

Limited published pharmacogenomic data on curcumin specifically, but several inferences from CYP and conjugation enzyme polymorphisms:

• UGT1A1 polymorphisms (Gilbert's syndrome, *28 carriers): UGT1A1 is one of curcumin's main glucuronidation pathways. Slow glucuronidators may have higher systemic curcumin exposure → potentially higher efficacy, potentially higher hepatotoxicity risk. Watch ALT/AST more carefully. Gilbert's is common (~5-10% of European descent).
• CYP3A4 / CYP3A5 variants: Carriers of CYP3A5 *3 (poor expressers — common in white/Nordic populations including Dylan's ancestry) already have lower CYP3A activity; curcumin further inhibits CYP3A → relevant for any CYP3A4-substrate co-medication. Magnitude small at Dylan's curcumin dose.
• **CYP2C9 2/3 carriers (slow metabolizers): Higher exposure of CYP2C9 substrates (warfarin, NSAIDs) when combined with curcumin. Relevant if Dylan ever needed warfarin or chronic NSAIDs.
• GSTM1 / GSTT1 null genotypes: Reduced glutathione transferase activity → less detoxification of reactive metabolites; theoretically higher hepatotoxicity risk with high-dose curcumin. ~50% of European-descent population is GSTM1-null. Practical impact: get baseline ALT/AST and recheck at 6 months.
• HLA-B*35:01: Associated with green-tea-extract DILI; possibly relevant for curcumin DILI risk by analogy. Not routinely tested on 23andMe.
• APOE4 status: Theoretical interest because curcumin's anti-amyloid action is most relevant in APOE4-driven AD risk. No human RCT has stratified curcumin response by APOE. If Dylan's June 2026 23andMe returns APOE4, the rationale strengthens; dose unchanged.
• MTHFR / COMT / DRD variants: No direct curcumin interaction.
• NRF2 / NFE2L2 variants: Interesting in theory — Nrf2 polymorphisms could modulate the antioxidant-amplifier effect — but no human RCT has stratified.

When 23andMe results land (~June 2026), key checks:

1. UGT1A1 status (Gilbert's marker) — if positive, monitor ALT/AST more closely.
2. APOE genotype — APOE4 strengthens cognitive rationale.
3. CYP3A5 status — relevant only if Dylan adds CYP3A4 substrate medications.

No pre-emptive dose adjustment expected.

Dylan's recommendation: KEEP Doctor's Best Curcumin Phytosome 500 mg from iHerb — already in V4, optimal form, lowest cost in tier, fits existing channel. No change needed.

If Dylan ever wants to upgrade beyond current dose, options in priority order:

1. Increase Doctor's Best to 2 caps/day (1000 mg Meriva = depression-trial dose) — adds ~$10/mo.
2. Layer Natural Factors Theracurmin 90 mg BID for the Small 2018 cognitive-PET protocol — adds ~$20/mo.
3. Switch to Thorne for audit-standard preference — same molecule, higher cost.

• Baseline (before starting / on June 2026 panel):

  • Liver panel (ALT, AST, ALP, GGT, total bilirubin) — most important. Establishes pre-curcumin baseline for the rare DILI risk.
  • hsCRP — primary efficacy marker for systemic inflammation; expect ↓ after 8-12 weeks.
  • IL-6 if available (specialty panel) — secondary inflammation marker.
  • Lipid panel (TC, LDL-C, HDL-C, TG) — expect mild improvements in dyslipidemia, neutral in healthy young adults.
  • Fasting glucose, HbA1c — expect mild improvements; verify no worsening.
  • Ferritin + serum iron + TIBC — baseline before chronic curcumin (iron chelation watch).
  • CBC — baseline (iron status, general).
  • MDA / oxidized LDL — optional oxidative stress markers; specialty panel.
  • BDNF (research-grade serum assay) — optional; rarely available clinically.
  • Subjective: morning joint stiffness rating, post-training DOMS rating (1-10 scale), recovery time after hard sparring, sleep quality, mood (PHQ-9 monthly).

• During use (6-month and annual cadence):

  • Liver panel (ALT, AST, ALP, GGT) — looking for stable; flag if any elevation.
  • hsCRP — looking for ↓ at 8-12 weeks and stable thereafter.
  • Ferritin — looking for stable; flag if ↓.
  • Lipid panel + glucose — looking for stable or improved.
  • Subjective DOMS / joint stiffness / recovery — looking for ↓.

• Post-cycle: N/A (no cycling).

For Dylan specifically: piggyback on the June 2026 baseline panel. No additional bloodwork solely for curcumin needed at this stage. The DILI risk is real but rare; routine ALT/AST every 6-12 months is the appropriate vigilance level.